-
Potential Acquisition At Biotech Sectors: Celgene, Onyx Pharmaceuticals, Pfizer, Amgen, Allergan, Merck, Exelix, Inovio Pharmaceuticals
Celgene Corporation (NASDAQ:CELG) declared that it has appeared as the leading treatment supplier for blood cancer. The firm worth has almost doubled in the previous year because of increasing sales of Revlimid and agreement of Pomalyst. Both drugs in the middle of the leaders in this industry and have combined peak sales potential of over…
-
Technicality in Biotech And Emerging Pharmaceutical Stocks; Gilead Sciences, Onyx, Pharmaceuticals, Amgen, Arena Pharmaceuticals, Celgene, Pharmacyclics, Regeneron, VIVUS, Biogen, Pfizer, GlaxoSmithKline , Merck, Novartis
Amid biotech as well as emerging pharmaceutical firms, Gilead Sciences, Inc. (NASDAQ:GILD) and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX saw the mainly significant surges in short interest amid the June 14 and June 28 settlement dates. The severe shares sold short in Amgen (NASDAQ:AMGN), Arena Pharmaceuticals (NASDAQ:ARNA), Celgene (NASDAQ:CELG), Pharmacyclics (NASDAQ:PCYC), Regeneron Pharmaceuticals (NASDAQ:REGN) and VIVUS (NASDAQ:VVUS)…
-
Drug Maker In Pressure: Merck & Co., Inc. (NYSE:MRK) Face Lawsuit of $100 million
A sales person for Merck & Co., Inc. (NYSE:MRK) filed court case of overi$100M sex discrimination against the drugmaker, asserting that it mainly distinguishes alongside pregnant employees and women among children. In a claim filed in U.S. District Court in New Jersey, the claimant, Kelli Smith asserts she was downgraded for taking maternity leave in…
-
Dow Components Chevron Corporation (NYSE:CVX) and Exxon Mobil Corporation (NYSE:XOM) Lifts U.S. Stocks
On Friday, the U.S. stock futures index indicated higher on the first day of the month, as the investors’ attention focused on the Labor department’s monthly jobs report which released on early morning. According to the economists polled by Reuters,anticipates non-farm payrolls surged by 155,000 in January, a recurrence of December’s gain. The unemployment rate…
-
FDA Rejects request against Pfizer Inc. (NYSE:PFE) Alzheimer’s drug
The U.S. Food and Drug Administration rejected a consumer advocacy group’s request to remove a Pfizer Inc. (NYSE:PFE) Alzheimer’s drug over efficacy and safety concerns, saying the shortage of drugs on the market may give reason for the side effects. The agency declined Public Citizen Inc.’s appeal that claimed a 23-milligram dose of Aricept, manufactured…
-
Pfizer Inc. (NYSE:PFE) suffers after providing Weak Outlook for 2012
Pfizer Inc. (NYSE:PFE) shares are under pressure today after reducing its forecast for 2012. The company has reported a tough third quarter hit by the loss of exclusivity on its smash hit Lipitor. Third-quarter profit declined 14 percent as compared to a year earlier to $3.2 billion, according to the world’s largest drug maker. The…
-
Finally Sprint Nextel (NYSE:S)’s Deal Rumors Turn True – (AMD, MRK, INTC)
Earnings of S&P 500 (INDEXSP:.INX) companies are seen falling 3 percent this quarter as compared to the same period a year ago, the first fall in three years. Financial results are predicted to have been negatively impacted by China’s weak growth and Europe’s debt crisis, which lately prompted the International Monetary Fund to reduce its…
-
Report: Cancer Replaces Heart Disease As No.1 Killer – (PFE, BMY, JNJ, MRK)
Cancer has surpassed heart disease as the leading cause of death among Hispanics in the U.S., likely revealing the large number of young, working-age Hispanics in America, according to a report released by the American Cancer Society Monday. Cancer society researchers performed study on federal death data for 2009 and concluded that 29,935 Hispanics died…
-
NIH Clinical Center in Maryland Declares Seventh Death from a Deadly Germ – (PFE, MRK, JNJ, BMY)
A deadly germ that was not treatable by the majority antibiotics has caused death of a seventh person at the National Institutes of Health Clinical Center in Maryland. The Washington Post declared about the death on Friday. NIH representatives told media that the boy from Minnesota died September 7. NIH told that the boy was…
-
Two Studies Reveal Bapineuzumab Also Have Some Potential Benefit – (PFE, JNJ, MRK, BMY)
Complete results of two important studies, one led by Dr. Reisa Sperling and other led by Dr. Stephen Salloway, now reveal that an experimental drug that was unable to stop mental decline in Alzheimer’s patients also disclosed some potential benefit. Researchers reported today a number of patients on the drug had gained stable levels of…